Companies › NKTR

NEKTAR THERAPEUTICS (NKTR)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0000906709 · EDGAR filings · Updated 2026-07-24

NEKTAR THERAPEUTICS (NKTR) has reported institutional ownership of 93.1%, with 208 institutional managers holding positions valued at $1.92B per the latest 13F reporting period. SEC filings include an active material impairment disclosure (8-K Item 2.06), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01).

Filings this week (2)

• 2026-07-24 — Insider transaction reported (Form 4)
• 2026-07-24 — Insider transaction reported (Form 4)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-02 — Insider transaction reported (Form 4)
• 2026-06-30 — Notice of proposed sale filed (Form 144)
• 2026-06-18 — Insider transaction reported (Form 4)
• 2026-06-17 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, NEKTAR THERAPEUTICS has 208 institutional holders and institutional ownership of 93.1%.

Insider activity

Insiders reported 34 transactions (0 buys, 26 sells) across 3 reporting insiders, with a net reported value of −$1.34M.

Data flags from SEC filings

Related companies

ULTRAGENYX PHARMACEUTICAL IN (RARE) · GENEDX HOLDINGS CORP COM CL A (WGS) · AMNEAL PHARMACEUTICALS INC (AMRX) · ADMA BIOLOGICS (ADMA) · SURGERY PARTNERS INC (SGRY) · RELAY THERAPEUTICS INC (RLAY)